Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-04-06 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于向银行申请授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shanghai Medicilon Inc. regarding the company's board approval to apply for a bank credit facility of up to 650 million RMB. It details the credit types, terms, and authorizations for management to execute related legal documents. The document is short (650 characters) and is an announcement of a financing activity, not a full financial report or detailed financial data. It fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising and financing activities.
2022-04-06 Chinese
美迪西：关于持股5%以上股东股份解除冻结的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the unfreezing of shares held by a shareholder owning more than 5% of the company. It details the lifting of judicial freeze on 100,000 shares held by shareholder Chen Chunlai, including dates and shareholding percentages. The document is short (963 characters) and focuses on shareholding status changes due to legal actions, not on financial results, management changes, or other report types. It does not contain financial statements or detailed financial data. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2022-03-22 Chinese
美迪西：关于预计2022年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2022. It includes details about the nature of the transactions, the approval process by the board and supervisory committee, independent directors' opinions, and the impact on the company. It does not contain financial statements or detailed financial performance data but rather focuses on disclosure of related party transactions and compliance with regulatory requirements. The document is a regulatory announcement about related party transactions, not a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS). The document length is under 5,000 characters and is an announcement, not the report itself.
2022-02-28 Chinese
美迪西：第三届监事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by Shanghai Medicilon Inc. It details the meeting date, attendance, legal compliance, and the approval of a proposal regarding expected related party transactions for 2022. The document is short (773 characters) and does not contain financial statements or detailed financial data. It is an official announcement of a board/committee decision rather than a full management report or financial report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or certification letter. The content aligns best with Board/Management Information (MANG), which covers announcements of board or senior management decisions and changes. Therefore, the classification is MANG with high confidence.
2022-02-28 Chinese
北京金诚同达（上海）律师事务所关于上海美迪西生物医药股份有限公司2022年第一次临时股东大会的法律意见书
Regulatory Filings
2022-02-28 Chinese
美迪西：公司章程（2022年修订）
Governance Information Classification · 95% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Shanghai Medicilon Inc. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and other governance matters. It is a comprehensive governance document that sets out the internal rules and regulations of the company. There is no indication that this is an annual report, financial report, or announcement of voting results. It is not a proxy statement or remuneration report. The content aligns with governance information about the company's internal rules and board structure. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, supporting a high confidence classification.
2022-02-28 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.